Literature DB >> 23684754

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.

Katherine R Tuttle, Cory Heilmann, Byron J Hoogwerf, Carl Brown, Pamela W Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23684754     DOI： 10.1053/j.ajkd.2013.03.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  10 in total

Review 1.  Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.

Authors:  Yahiya Y Syed; Paul L McCormack
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 2.  Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.

Authors:  Joshua J Neumiller; Radica Z Alicic; Katherine R Tuttle
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

3.  Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.

Authors:  Katherine R Tuttle; Brian Rayner; Mark C Lakshmanan; Anita Y M Kwan; Manige Konig; Linda Shurzinske; Fady T Botros
Journal:  Kidney360       Date:  2020-12-08

Review 4.  Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

5.  Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Authors:  Katherine R Tuttle; T Dwight McKinney; Jaime A Davidson; Greg Anglin; Kristine D Harper; Fady T Botros
Journal:  Diabetes Obes Metab       Date:  2016-11-24       Impact factor: 6.577

6.  Management of Hyperglycemia in Diabetic Kidney Disease.

Authors:  Joshua J Neumiller; Irl B Hirsch
Journal:  Diabetes Spectr       Date:  2015-08

7.  Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.

Authors:  Leigh MacConell; Kate Gurney; Jaret Malloy; Ming Zhou; Orville Kolterman
Journal:  Diabetes Metab Syndr Obes       Date:  2015-05-18       Impact factor: 3.168

Review 8.  Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.

Authors:  Samuel S Grossman
Journal:  Adv Ther       Date:  2014-02-18       Impact factor: 3.845

9.  Diabetic kidney disease: a report from an ADA Consensus Conference.

Authors:  Katherine R Tuttle; George L Bakris; Rudolf W Bilous; Jane L Chiang; Ian H de Boer; Jordi Goldstein-Fuchs; Irl B Hirsch; Kamyar Kalantar-Zadeh; Andrew S Narva; Sankar D Navaneethan; Joshua J Neumiller; Uptal D Patel; Robert E Ratner; Adam T Whaley-Connell; Mark E Molitch
Journal:  Diabetes Care       Date:  2014-10       Impact factor: 19.112

Review 10.  Emerging utility of once-weekly exenatide in patients with type 2 diabetes.

Authors:  Aditya Goud; Jixin Zhong; Sanjay Rajagopalan
Journal:  Diabetes Metab Syndr Obes       Date:  2015-10-21       Impact factor: 3.168
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.